Aquestive Therapeutics (NASDAQ:AQST) is a specialty pharmaceutical company dedicated to developing and commercializing differentiated products that address patients' unmet needs and improve their quality of life. Utilizing its proprietary PharmFilm® technology, Aquestive enables the delivery of drugs through films placed under the tongue or inside the cheek, offering an innovative alternative to traditional administration methods. The company’s portfolio comprises treatments for conditions such as epilepsy and amyotrophic lateral sclerosis (ALS), striving to expand its impact through ongoing research and development projects. Aquestive Therapeutics aims to transform the way medicines are delivered, focusing on creating patient-friendly, effective solutions for complex health challenges.